XCell Therapeutics Inc is a Korea-based company primarily engaged in the manufacture and distribution of cell culture mediums. The Company is mainly engaged in the provision of dermal papilla cells (DPC), keratinocytes, exosomes and other dedicated mediums. Additionally, the Company is engaged in the manufacture and distribution of virus transport mediums. The Company sells its products in domestic and overseas markets.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
18/09/26	KRW 1,017.00	0.00%	57,352
17/09/26	KRW 1,017.00	-0.10%	50,750
16/09/26	KRW 1,018.00	+0.10%	21,124
15/09/26	KRW 1,017.00	+0.99%	65,854
14/09/26	KRW 1,007.00	-0.89%	62,569

End-of-day quote Korea S.E.

More quotes

End-of-day quote Korea S.E. 18/09/2026			5-day change	1st Jan Change
1,017.00 ^KRW	0.00%		+0.10%	-38.77%

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI

Market Cap	17.59B 12.66M 11.04M 10.42M 9.47M 17.74M 1.21B 17.81M 125M 48.19M 618M 47.56M 46.5M 1.99B	P/E 2024	-4.26x	P/E 2025	-1.77x
Enterprise Value	16.17B 11.64M 10.15M 9.58M 8.7M 16.3M 1.12B 16.37M 115M 44.3M 568M 43.72M 42.75M 1.83B	EV / Sales 2024	21.3x	EV / Sales 2025	14x
Free-Float	88.23%	Yield 2024 *	-	Yield 2025	-

14/08/25	Xcell Therapeutics to conduct capital increase of 15 billion won	RE
22/11/24	Gencurix Inc. announced that it expects to receive KRW 899.999158 million in funding from Xcell Therapeutics Inc.	CI
16/07/24	Xcell Therapeutics Shares Fall 4.7% Below Offering Price on Kosdaq Debut	MT
08/07/24	Xcell Therapeutics Inc. has completed an IPO in the amount of KRW 16.18 billion.	CI

1 week	+0.10%
Current month	-14.68%
1 month	-23.53%
3 months	-23.76%
6 months	-30.10%
Current year	-38.77%

Xcell Therapeutics Inc. Stock

Stocks

A373110

KR7373110006

Pharmaceuticals

Valuation: Xcell Therapeutics Inc.

Chart: Xcell Therapeutics Inc.

Latest news: Xcell Therapeutics Inc.

News in other languages: Xcell Therapeutics Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Xcell Therapeutics Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

1 week	951	1,046
1 month	951	1,482
Current year	951	2,050
1 year	951	4,035
3 years	951	12,900
5 years	951	12,900
10 years	951	12,900

Manager	Title	Age	Since
U-Ri Lee CEO	Chief Executive Officer	54	01/09/2016
Hae-Min Jeong CTO	Chief Tech/Sci/R&D Officer	40	-
Soo-Rim Oh COO	Chief Operating Officer	65	-

Director	Title	Age	Since
Jong-Min Lee BRD	Director/Board Member	48	27/03/2026
Mahn-Soon Hwang BRD	Director/Board Member	56	-
U-Ri Lee BRD	Director/Board Member	54	01/09/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
XCELL THERAPEUTICS INC.	0.00%	+0.10%	-68.56%	-	12.66M
ELI LILLY AND COMPANY	+0.04%	+3.34%	+51.12%	+101.82%	1,028B
JOHNSON & JOHNSON	-0.09%	+1.66%	+55.02%	+66.18%	651B
ABBVIE INC.	-0.02%	+2.66%	+18.91%	+71.47%	466B
ROCHE HOLDING AG	-1.22%	+3.66%	+36.44%	+38.32%	346B
NOVARTIS AG	-0.79%	+2.73%	+19.03%	+25.08%	266B
ASTRAZENECA PLC	+0.58%	+6.76%	+11.13%	+16.52%	259B
AMGEN INC.	+1.55%	+2.20%	+39.81%	+46.55%	208B
NOVO NORDISK A/S	+0.79%	+1.84%	-28.27%	-56.71%	191B
GILEAD SCIENCES, INC.	-0.52%	+4.45%	+32.12%	+98.51%	186B
Average	+0.18%	+3.03%	+16.68%	+45.30%	360.17B
Weighted average by Cap.	+0.23%	+3.09%	+35.15%	+61.76%

	2024	2025
Net sales	1.93B 1.39M 1.21M 1.15M 1.04M 1.95M 134M 1.96M 13.73M 5.3M 67.93M 5.23M 5.11M 219M	1.95B 1.4M 1.22M 1.16M 1.05M 1.97M 135M 1.97M 13.84M 5.34M 68.44M 5.27M 5.15M 220M
Net income	-9.54B -6.87M -5.99M -5.66M -5.14M -9.62M -659M -9.66M -67.75M -26.14M -335M -25.8M -25.23M -1.08B	-10.93B -7.87M -6.86M -6.48M -5.88M -11.02M -755M -11.06M -77.58M -29.94M -384M -29.55M -28.89M -1.23B
Net Debt	-3.1B -2.23M -1.95M -1.84M -1.67M -3.13M -214M -3.14M -22.01M -8.49M -109M -8.38M -8.2M -350M	-1.42B -1.02M -891K -841K -764K -1.43M -98.04M -1.44M -10.08M -3.89M -49.84M -3.84M -3.75M -160M